- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01337596
A Study of LY2951742 in Healthy Volunteers
8. oktober 2018 opdateret af: Eli Lilly and Company
A Safety, Tolerability, and Pharmacokinetic Study of Single, Escalating Subcutaneous Doses of LY2951742 in Healthy Volunteers
To evaluate the safety and tolerability of LY2951742 given as single or multiple subcutaneous injection in healthy male subjects
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
63
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Leuven, Belgien
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 55 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Han
Beskrivelse
Inclusion Criteria:
- Are healthy Caucasian males, as determined by medical history and physical examination
- Agree to use a reliable method of birth control (e.g. condom AND additional contraception method to be used by respective partner) during the study and for 3 months following the last dose of the investigational product
- Have a body mass index (BMI) greater than 19 kilogram/square meter (kg/m^2)
- Have clinical laboratory test results within normal reference range for the population or investigator site
- Have venous access sufficient to allow for blood sampling
- Are willing to follow study procedures including no drugs (exception of study drug) 72 hours prior to initiation of the laser doppler imaging (LDI) procedure, no chocolate, alcohol or caffeine containing products 12 hours prior to initiation of the laser doppler imaging (LDI) procedure, and complete a 4 hour fast prior to initiation of the laser doppler imaging (LDI) procedure
- Have suitable skin characteristics for the dermal capsaicin challenge and have demonstrated a 100 percent increase in dermal flow following capsaicin challenge as part of the screening procedures and measured by laser doppler imaging (LDI)
Exclusion Criteria:
- Are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- Are persons who have previously received the investigational product in this study, have completed or withdrawn from this study investigating LY2951742
- Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study including QTc greater than 450 milliseconds (msec) (male), history of congenital long QT syndrome or other conduction abnormality
- Have abnormal vital signs as determined by the investigator
- Have a history or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders (including migraine) that would constitute a risk when taking the study medication; or of interfering with the interpretation of data study
- Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
Show evidence of:
- Human immunodeficiency virus infection and/or positive human immunodeficiency virus (HIV) antibodies
- Hepatitis C and/or positive hepatitis C antibody
- Hepatitis B and/or positive hepatitis B surface antigen
- Intend to use over-the-counter or prescription medication that may interfere with study safety assessments or other measurements within 7 days prior to dosing and during the study (example: systemic glucocorticoids, immunomodulatory drugs, drugs with propensity for dermal reactions, and drugs with known liver toxicity).
- Have donated blood of more than 500 milliliter (mL) or has undergone major surgery
- The use of caffeine containing products and alcohol is not allowed from 12 hours prior to all study visits and during in clinic stays. All other times, alcohol consumption and caffeine intake are limited to no more than 2 alcoholic beverages or equivalent (beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits (25 milliliter [mL/1 ounce]) per day and caffeinated beverages will be limited to no more than 2 units per day amounts (1 unit=120 milligrams [mg] of caffeine). Strenuous activity is not allowed from 1 week prior to admission until the follow-up visit.
- Are smokers within the previous 6 months
- Have received treatment with biologic agents (such as monoclonal antibodies) within 3 months or 5 half-lives (whichever is longer)prior to dosing or have received a vaccination within 1 month
- Have a history of multiple or severe allergies or has had an anaphylactic reaction or intolerability to prescription or non-prescription drugs or food
- Are immunocompromised
- Have had cancer or within the past 5 years
- Have a history of significant allergies, in particular to ethanol or sensitivity to the fruits of capsicum plants (example: chili peppers)
- Have eczema, scleroderma, psoriasis, dermatitis, keloids, tumors, ulcers, burns, flaps, or grafts on their forearm or other abnormality of the skin which may interfere with the study assessments
- Cannot avoid excess tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study and cannot cover forearms for 24 hours prior to treatment period
- Have excessive hair growth on the volar surface of the forearm or subjects currently using lotions, oils, depilatory preparations, or other topical treatments on a regular basis which cannot be discontinued for the duration of the study; subject has used any topical treatments within 7 days of the start of the study
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Single dose 1 milligram (mg) LY2951742
Administered single subcutaneous injection
|
Administered subcutaneously
|
Eksperimentel: Single dose 5 mg LY2951742
Administered single subcutaneous injection
|
Administered subcutaneously
|
Eksperimentel: Single dose 25 mg LY2951742
Administered single subcutaneous injection
|
Administered subcutaneously
|
Eksperimentel: Single dose 75 mg LY2951742
Administered single subcutaneous injection
|
Administered subcutaneously
|
Eksperimentel: Single dose 200 mg LY2951742
Administered single subcutaneous injection
|
Administered subcutaneously
|
Eksperimentel: Single dose 600 mg LY2951742
Administered single subcutaneous injection
|
Administered subcutaneously
|
Placebo komparator: Single dose placebo
Administered single subcutaneous injection
|
Indgives subkutant
|
Placebo komparator: Multiple dose placebo
Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
|
Indgives subkutant
|
Eksperimentel: 150 mg LY2951742
Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
|
Administered subcutaneously
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants With Clinically Significant Effects
Tidsramme: Baseline up to 6 months (study completion)
|
Clinically significant effects were defined as serious and other non-serious adverse events (AEs).
A summary of serious and all other non-serious AEs is located in the Reported Adverse Events module.
|
Baseline up to 6 months (study completion)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Single Dose Pharmacokinetics of LY2951742 Maximal Concentration (Cmax)
Tidsramme: Day 1 up to Day 84 or early discontinuation
|
Day 1 up to Day 84 or early discontinuation
|
Single Dose Pharmacokinetics of LY2951742 Area Under the Curve (AUC)
Tidsramme: Day 1 up to Day 84 or early discontinuation
|
Day 1 up to Day 84 or early discontinuation
|
Multiple Dose Pharmacokinetics of LY2951742 Maximal Concentration (Cmax)
Tidsramme: Day 43 up to Day 57
|
Day 43 up to Day 57
|
Multiple Dose Pharmacokinetics of LY2951742 Area Under the Curve (AUC)
Tidsramme: Day 43 up to Day 57
|
Day 43 up to Day 57
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. april 2011
Primær færdiggørelse (Faktiske)
1. april 2012
Studieafslutning (Faktiske)
1. april 2012
Datoer for studieregistrering
Først indsendt
15. april 2011
Først indsendt, der opfyldte QC-kriterier
15. april 2011
Først opslået (Skøn)
19. april 2011
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
20. februar 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
8. oktober 2018
Sidst verificeret
1. maj 2012
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- 14248
- I5Q-MC-CGAA (Anden identifikator: Eli Lilly and Company)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
West Penn Allegheny Health SystemAfsluttetAstma | Allergisk rhinitisForenede Stater
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AfsluttetSund og rask | Kropssammensætning
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien